Vir Biotechnology, Inc. (VIR)

Over the past six months, Vir Biotechnology's stock price has been influenced by several events. The company reported a larger-than-expected loss in Q1 2026, but the stock rose due to clinical progress and partnerships. The Chairman of the Board sold shares as part of a pre-planned trading plan. The company closed a global strategic collaboration with Astellas for the prostate cancer treatment VIR-5500 and announced the dosing of the first patient in Phase 1 dose-expansion cohorts for VIR-5500. The CEO sold shares. The stock price increased after updated data from an early-stage trial for VIR-5500 demonstrated efficacy. Vir Biotechnology announced a global strategic collaboration with Astellas to advance VIR-5500 for prostate cancer and reported its Q4 and full-year 2025 financial results. Analyst price targets have generally increased due to the Astellas collaboration, positive VIR-5500 data, and progress in hepatitis D programs. The stock has seen a 51.2% increase since the beginning of 2026 and a 101% gain over the past six months as of May 6, 2026.

Information regarding specific demand seasonality for Vir Biotechnology's products and services is not readily available. Demand for its biopharmaceutical products is typically driven by disease prevalence and medical need, rather than seasonal fluctuations.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on leveraging the immune system to develop medicines for serious infectious diseases and cancer. The company's business model centers on powering the immune system to address critical unmet medical needs, utilizing technologies like a next-generation antibody platform, the dAIsY AI engine, and PRO-XTEN protease-releasable masking technology. Its major product pipeline includes therapies for Chronic Hepatitis Delta, Oncology (Solid Tumors), HIV, Influenza A and B, COVID-19, Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (MPV), and Human Papillomavirus (HPV).

Vir Biotechnology is headquartered in San Francisco, California, and has an innovation lab and offices in St. Louis, Missouri. The company develops therapeutic products for the United States and internationally. Its chronic hepatitis delta therapy, tobevibart + elebsiran, has been licensed to Norgine for commercialization in Europe, Australia, and New Zealand.

In the past year, Vir Biotechnology has maintained a generally positive brand reputation, driven by its clinical advancements and strategic partnerships. Collaborations with companies like Astellas and Norgine have been viewed as validation of Vir's oncology approach and have expanded its market reach. Positive early clinical trial data for VIR-5500 in prostate cancer and encouraging Phase 2 SOLSTICE data in chronic hepatitis delta have further bolstered its reputation. The company's investigational combination therapy for chronic hepatitis delta has also received significant regulatory recognition. No significant negative events impacting Vir Biotechnology's reputation were identified during this period.

Vir Biotechnology's ownership is a mix of institutional, individual, and retail investors. Institutional investors hold a significant portion, ranging from approximately 51.2% to 83.01% of the company's stock. Major institutional owners include BlackRock, Inc., SB Investment Advisers (UK) Ltd, Arch Venture Management LLC, Vanguard Group Inc, Glaxosmithkline Plc (GSK Equity Investments, Limited), and State Street Corp. Individual insiders hold between 4.53% and 10.55% of the stock. The largest individual shareholder is Alaska Permanent Fund Corp, owning 11.95% of the company's shares. Retail investors hold approximately 22.8% to 55.89% of the stock.